Banco Bilbao Vizcaya Argentaria S.A. Reduces Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Banco Bilbao Vizcaya Argentaria S.A. trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 37,676 shares of the biopharmaceutical company’s stock after selling 492 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Regeneron Pharmaceuticals were worth $19,772,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Proficio Capital Partners LLC boosted its stake in Regeneron Pharmaceuticals by 6.2% during the 1st quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company’s stock valued at $207,000 after acquiring an additional 19 shares during the last quarter. Cove Private Wealth LLC increased its holdings in Regeneron Pharmaceuticals by 4.5% in the first quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 20 shares during the last quarter. Marino Stram & Associates LLC increased its holdings in Regeneron Pharmaceuticals by 5.3% in the second quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 20 shares during the last quarter. Activest Wealth Management raised its stake in Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 21 shares in the last quarter. Finally, CX Institutional lifted its holdings in Regeneron Pharmaceuticals by 7.9% during the 2nd quarter. CX Institutional now owns 302 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 22 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $694.99 on Friday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $803.41. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.72. The firm has a market capitalization of $73.04 billion, a price-to-earnings ratio of 16.64, a price-to-earnings-growth ratio of 2.03 and a beta of 0.31. The business has a 50 day simple moving average of $596.36 and a 200 day simple moving average of $570.46.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. During the same period in the previous year, the business earned $12.46 earnings per share. The company’s revenue was up .9% on a year-over-year basis. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.43%.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research note on Tuesday, September 2nd. Wells Fargo & Company boosted their price objective on shares of Regeneron Pharmaceuticals from $580.00 to $615.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 29th. Sanford C. Bernstein lifted their target price on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a research note on Wednesday, August 27th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Royal Bank Of Canada boosted their price objective on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research report on Wednesday, October 29th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $789.91.

Insiders Place Their Bets

In other news, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares in the company, valued at approximately $2,757,503.19. This trade represents a 9.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the sale, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. This trade represents a 73.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.